Bayer Ag Na Stock Price To Sales

BAYN Stock  EUR 19.42  0.06  0.31%   
Bayer AG NA fundamentals help investors to digest information that contributes to Bayer AG's financial success or failures. It also enables traders to predict the movement of Bayer Stock. The fundamental analysis module provides a way to measure Bayer AG's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bayer AG stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bayer AG NA Company Price To Sales Analysis

Bayer AG's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Bayer AG Price To Sales

    
  1.00 X  
Most of Bayer AG's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bayer AG NA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Based on the latest financial disclosure, Bayer AG NA has a Price To Sales of 1.0013 times. This is 95.32% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to sales for all Germany stocks is 91.23% higher than that of the company.

Bayer Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bayer AG's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bayer AG could also be used in its relative valuation, which is a method of valuing Bayer AG by comparing valuation metrics of similar companies.
Bayer AG is currently under evaluation in price to sales category among its peers.

Bayer Fundamentals

About Bayer AG Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bayer AG NA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bayer AG using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bayer AG NA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Bayer Stock

Bayer AG financial ratios help investors to determine whether Bayer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.